Treatment with somatostatin

Yun et al, 199951823 patients with type 1 diabetes
Aged 36.1 ± 10.73 with octreotide, 33.25 ± 13.4 years with no octreotide
Patients with stuporous or comatose mental state were excluded
  1. IV infusion of low-dose insulin and 50 μg of SC octreotide every 6 hours
  2. IV infusion of low-dose insulin, no octreotide
    Octreotide is a synthetic long- acting somatostatin
Time to recovery of clinical and laboratory signs of ketoacidosis, hypoglycaemia, acidosis and ketosisNo statistically significant difference seen in the time to recovery of hypoglycaemia: octreotide (n = 7) 8.9 ± 3.21 vs. no octreotide (n = 8) 18.8 ± 13.2 hours, p = 0.089
No statistically significant difference seen in the time to recovery of acidosis: octreotide 24.0 ± 12.6 vs. no octreotide 33.2 ± 13.9 hours, p = 0.82
Difference seen in the time to recovery of ketonuria: octreotide 38.0 ± 32.0 vs. no octreotide 68.3 ± 26.0 hours, p = 0.049, borderline statistically significant
Unknown how allocation to groups took place
Possibly groups were biased as 3/7 in the octreotide group had alcohol as a precipitating factor whereas this was not the case in the no octreotide group
Numbers in study do not add up: 8 patients in the no octreotide group were not included in the results but it was not explained why
Intervention study not randomisedIIa

From: Evidence tables

Cover of Type 1 Diabetes
Type 1 Diabetes: Diagnosis and Management of Type 1 Diabetes in Children and Young People.
NICE Clinical Guidelines, No. 15.2.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2004 Sep.
Copyright © 2004, National Collaborating Centre for Women’s and Children’s Health.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Collaborating Centre for Women’s and Children’s Health to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.